[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100506460":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":18,"locations":27,"responsibleParty":47,"collaborators":18,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":18,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":71,"overallStatus":30,"whyStopped":18,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Wonju Severance Christian Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"nafamostat","ACTIVE_COMPARATOR","Patients received dialysis through nafamostat",[13],"Drug: Nafamostat Mesylate",{"label":15,"type":16,"description":17,"interventionNames":18},"Cnoxane","NO_INTERVENTION","Patients received dialysis through cnoxan",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Nafamostat Mesylate","Comparison effect of nafamostat and cnoxan",[9],[26],"cnoxan",[28],{"facility":29,"status":30,"city":31,"state":32,"zip":33,"country":34,"countryCode":18,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Yonsei Unviersity Wonju College of Medicin","RECRUITING","Wŏnju","Kangwondo","26426","South Korea",{"type":36,"coordinates":37},"Point",[38,39],127.94528,37.35139,{"lat":39,"lon":38},[42],{"name":43,"role":44,"phone":45,"phoneExt":18,"email":46},"Jun Young Lee","CONTACT","820337410935","junyoung07@yonsei.ac.kr",{"type":48,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100506460","the-safety-of-nafamostat-mesylate-for-patients-with-high-risk-bleeding-undergoing-hemodialysis-a-pilot-study-100506460",false,"NCT05874674","The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Undergoing Hemodialysis: A Pilot Study","The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Diathesis Undergoing Hemodialysis: A Pilot Study","Nafamostat","Inclusion Criteria:\n\n* platelet below 10k PTT above 60 second INR above 20 patient with bleeding (epistaxis, orbital bleeding, hematuria) recent brain hemorrhage (within 6 months) receiving anticoagulant therapy (coumadin or NOAC) dual antiplatelet agent users received major surgery within one month\n\nExclusion Criteria:\n\n* cancer liver cirrhosis pregnancy drug allergy current bleeding on major organ (brain, gastrointestinal)",true,"ALL","18 Years","99 Years",{"count":62,"type":63},100,"ESTIMATED","INTERVENTIONAL",[66],"NA","Comparison nafamostat and low molecular weight heparin among dialysis patients",[69,70],"Dialysis; Complications","Bleeding",[72,73,9,74],"dialysis","bleeding","heaprin","2024-07-28",{"date":77,"type":78},"2024-07-30","ACTUAL",{"date":80,"type":78},"2023-12-01",{"date":82,"type":63},"2026-12-31",{"name":5,"class":6},1]